Discounted Cash Flow (DCF) Analysis Unlevered

Rain Therapeutics Inc. (RAIN)

$7.98

+0.26 (+3.37%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 7.98 | undervalue

Operating Data

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Revenue (%)
EBITDA --------
EBITDA (%)
EBIT --------
EBIT (%)
Depreciation --------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash --------
Total Cash (%)
Account Receivables --------
Account Receivables (%)
Inventories --------
Inventories (%)
Accounts Payable --------
Accounts Payable (%)
Capital Expenditure --------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 7.98
Beta 0.000
Diluted Shares Outstanding 10.66
Cost of Debt
Tax Rate -0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.529
Total Debt 0.41
Total Equity 85.04
Total Capital 85.46
Debt Weighting 0.48
Equity Weighting 99.52
Wacc

Build Up Free Cash

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
EBITDA --------
EBIT --------
Tax Rate 0.00%0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%
EBIAT --------
Depreciation --------
Accounts Receivable --------
Inventories --------
Accounts Payable --------
Capital Expenditure -0.14-0.02-2.63-----
UFCF --------
WACC
PV UFCF --------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.54
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -24.37
Equity Value -
Shares Outstanding 10.66
Equity Value Per Share -